RESUMEN
OBJECTIVE: To quantify phytochemicals using liquid chromatography and mass spectroscopy (LCMS) analysis and explore the therapeutic effect of Aesculus hippocastanum L. (AH) seeds ethanolic extract against gastric ulcers in rats. METHODS: Preliminary phytochemical testing and LCMS analysis were performed according to standard methods. For treatment, the animals were divided into 7 groups including normal control, ulcer control, self-healing, AH seeds low and high doses, ranitidine and per se groups. Rats were orally administered with 10 mg/kg of indomethacin, excluding the normal control group (which received 1% carboxy methyl cellulose) and the per se group (received 200 mg/kg AH seeds extract). The test group rats were then given 2 doses of AH seeds extract (100 and 200 mg/kg, respectively), while the standard group was given ranitidine (50 mg/kg). On the 11th day, rats in all groups were sacrificed, and their stomach was isolated to calculate the ulcer index, and other parameters such as blood prostaglandin (PGE2), tissue superoxide dismutase (SOD), catalase (CAT), malonyldialdehyde (MDA), and glutathione (GSH). All isolated stomach tissues were analyzed for histopathological findings. RESULTS: The phytochemical examination shows that the AH seeds contain alkaloids, flavonoids, saponins, phenolic components, and glycosides. LCMS analysis confirms the presence of quercetin and rutin. The AH seeds extract showed significant improvement in gastric mucosa conditions after indomethacin-induced gastric lesions (P<0.01). Further marked improvement in blood PGE2 and antioxidant enzymes, SOD, CAT, MDA and GSH, were observed compared with self-healing and untreated ulcer-induced groups (P<0.01). Histopathology results confirmed that AH seeds extract improved the mucosal layer and gastric epithelial membrane in treated groups compared to untreated ulcer-induced groups. CONCLUSIONS: LCMS report confirms the presence of quercetin and rutin in AH seeds ethanolic extract. The therapeutic effect of AH seeds extract against indomethacin-induced ulcer in rat model indicated the regenerated membrane integrity, with improved cellular functions and mucus thickness. Further, improved antioxidant enzyme level would help to reduce PGE2 biosynthesis.
Asunto(s)
Aesculus , Úlcera Gástrica , Ratas , Animales , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/tratamiento farmacológico , Úlcera Gástrica/patología , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Ranitidina/efectos adversos , Úlcera/tratamiento farmacológico , Quercetina , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Extractos Vegetales/química , Indometacina/uso terapéutico , Glutatión , Superóxido Dismutasa , Rutina/efectos adversos , Prostaglandinas/efectos adversos , Fitoquímicos/uso terapéuticoRESUMEN
Age-related sarcopenia is a progressive and generalized skeletal muscle disorder associated with adverse outcomes. Herein, we evaluate the effects of a combination of electrical muscle stimulation (EMS) and a whey-based nutritional supplement (with or without polyphenols and fish oil-derived omega-3 fatty acids) on muscle function and size. Free-living elderly participants with mobility limitations were included in this study. They received 2 sessions of EMS per week and were randomly assigned to ingest an isocaloric beverage and capsules for 12 weeks: (1) carbohydrate + placebo capsules (CHO, n = 12), (2) whey protein isolate + placebo capsules (WPI, n = 15) and (3) whey protein isolate + bioactives (BIO) capsules containing omega-3 fatty acids, rutin, and curcumin (WPI + BIO, n = 10). The change in knee extension strength was significantly improved by 13% in the WPI + BIO group versus CHO on top of EMS, while WPI alone did not provide a significant benefit over CHO. On top of this, there was the largest improvement in gait speed (8%). The combination of EMS and this specific nutritional intervention could be considered as a new approach for the prevention of sarcopenia but more work is needed before this approach should be recommended. This trial was registered at the Japanese University Hospital Medical Information Network (UMIN) clinical trial registry (UMIN000008382).
Asunto(s)
Curcumina , Terapia por Estimulación Eléctrica , Ácidos Grasos Omega-3 , Fuerza Muscular , Proteína de Suero de Leche , Anciano , Anciano de 80 o más Años , Curcumina/administración & dosificación , Curcumina/efectos adversos , Curcumina/uso terapéutico , Suplementos Dietéticos , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/efectos adversos , Ácidos Grasos Omega-3/uso terapéutico , Femenino , Anciano Frágil , Humanos , Masculino , Persona de Mediana Edad , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Rutina/administración & dosificación , Rutina/efectos adversos , Rutina/uso terapéutico , Sarcopenia/terapia , Proteína de Suero de Leche/administración & dosificación , Proteína de Suero de Leche/efectos adversos , Proteína de Suero de Leche/uso terapéuticoRESUMEN
INTRODUCTION: Vigorous and prolonged exercise such as marathon running increases inflammatory markers and the risk of upper respiratory illness (URI) in athletes. Nutritional supplements are being tested as countermeasures of exercise-induced inflammation and immune dysfunction. METHODS: In this prospective randomized, double-blind, placebo-controlled phase I trial, healthy male runners (N = 138, age 42 ± 11 yr) were supplemented with rutoside (600-1200 mg·d) and hydrolytic enzymes (540-1080 mg·d bromelain, 288-576 mg·d trypsin) (WOB) or placebo (PL) for 1 wk before and 2 wk after the Munich Marathon 2013. Blood samples were collected 5 wk prerace and immediately, 24 h, and 72 h postrace and analyzed for inflammation biomarkers (interleukins [IL] 6 and 10, high-sensitivity C-reactive protein, and leukocytes). URI rates, assessed by the Wisconsin Upper Respiratory Symptom Survey, were compared between the study groups during the 2-wk period after the marathon race. URI was defined if the Wisconsin Upper Respiratory Symptom Survey score was equal or greater than seven, representing either one severe symptom or seven mild symptoms. RESULTS: Immediately postrace, the increase of IL-6 was not significantly different between the WOB and the PL groups (median [interquartile range]: WOB, 33.8 [22.5-58.8] ng·L; PL, 35.6 [24.8-61.29] ng·L; P = 0.758). No significant group differences were observed for increases of IL-10, high-sensitivity C-reactive protein, or leukocytes pre- to postrace (all P > 0.05). From race day until 2 wk after the marathon race, the percentage of individuals with at least one URI did not significantly differ between the groups (WOB, 50.0%; PL, 51.5%; P = 0.859). CONCLUSION: Supplementation with rutoside and hydrolytic enzymes before and after a marathon race did not attenuate postrace inflammation or decrease URI incidence in nonelite male marathon runners.
Asunto(s)
Bromelaínas/administración & dosificación , Suplementos Dietéticos , Inflamación/prevención & control , Resistencia Física/fisiología , Carrera/fisiología , Rutina/administración & dosificación , Tripsina/administración & dosificación , Adulto , Bromelaínas/efectos adversos , Proteína C-Reactiva/metabolismo , Suplementos Dietéticos/efectos adversos , Método Doble Ciego , Humanos , Inflamación/sangre , Interleucina-10/sangre , Interleucina-6/sangre , Recuento de Leucocitos , Leucocitos/metabolismo , Masculino , Resistencia Física/inmunología , Estudios Prospectivos , Infecciones del Sistema Respiratorio/sangre , Infecciones del Sistema Respiratorio/prevención & control , Rutina/efectos adversos , Tripsina/efectos adversosRESUMEN
INTRODUCTION: Systemic enzyme therapy can play an important role in maintaining normal inflammatory processes within the body and thereby helps support and speed up healing. In the course of the anti-inflammatory action, enzymes degrade damaged cells and necrotic material and, through the inactivation of mediators and toxic products, they restrict the edema and pain. METHOD: The study conducted at Grant Medical College, Mumbai, India was a clinical trial comparing the efficacy and tolerability of three oral enzyme treatment groups-oral tablets containing trypsin:chymotrypsin (TC) (Chymoral Forte®), serratiopeptidase (S) 5 mg oral tablets, and oral enzyme tablets containing trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg (TBR)-to evaluate their healing potential in surgical wounds after orthopedic surgery. RESULTS: A total of 75 patients were screened, randomized, and divided into three groups in 1:1:1 ratio receiving either of the three treatments. In the TC group, erythema was significantly reduced from 3.44 on day 3 to 1.16 on day 10 (p < 0.01). There was significantly better reduction in erythema scores in the TC group as compared to S and TBR groups (p < 0.05) at each follow-up visit. Similarly reduction in the local irritation, wound discharge, edema, induration, and tenderness score with TC treatment at the end of the study was significantly higher than that observed in the other two groups. In addition TC showed significant reduction in pain on the VAS scale (p < 0.01). Global assessment of response to therapy for efficacy and tolerability was reported to be good to excellent in 88% and 92% of the patients on TC as compared to 12% and 8% with S and 12% and 8% with TBR. CONCLUSION: TC provides a better resolution of symptoms of inflammation after orthopedic surgery as compared to S and TBR, thus facilitating better wound healing. Further studies are warranted to confirm the findings. TRIAL REGISTRATION: Clinical Trial Registry of India (Reg. No. CTRI/2011/07/001920).
Asunto(s)
Antiinflamatorios/uso terapéutico , Bromelaínas/uso terapéutico , Quimotripsina/uso terapéutico , Péptido Hidrolasas/uso terapéutico , Rutina/uso terapéutico , Tripsina/uso terapéutico , Heridas y Lesiones/tratamiento farmacológico , Adulto , Bromelaínas/administración & dosificación , Bromelaínas/efectos adversos , Quimotripsina/administración & dosificación , Quimotripsina/efectos adversos , Combinación de Medicamentos , Quimioterapia Combinada , Eritema/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Péptido Hidrolasas/administración & dosificación , Péptido Hidrolasas/efectos adversos , Estudios Prospectivos , Rutina/administración & dosificación , Rutina/efectos adversos , Tripsina/administración & dosificación , Tripsina/efectos adversos , Cicatrización de Heridas/efectos de los fármacosRESUMEN
In order to investigate the toxicity of rutin-rich dough from the Tartary buckwheat variety 'Manten-Kirari,' acute and subacute toxicity studies (10,000 and 5,000 mg/kg flour, respectively) were performed using rats. In the acute toxicity study, no toxic symptoms were observed and no rats died during the test. Body weight in the 'Manten-Kirari'-treated group was not significantly different when compared with that of the control group. On pathologico-anatomic observation, no unusual symptoms were observed in the 'Manten-Kirari'-treated group when compared with the control group. In the subacute toxicity study, no toxic symptoms were observed and no rats died during the test. Body weight and food intake in the 'Manten-Kirari'-treated and common buckwheat groups were not significantly different when compared with the control group. However, some investigated properties, such as urine protein and serum albumin, were significantly different in the 'Manten-Kirari' and common buckwheat groups when compared with the control group. However, these changes were not caused by toxicity, but by transient changes. On pathologico-anatomic observation, some abnormalities were observed in the liver, kidneys, heart, lung, bronchi and pituitary gland in some rats. However, the incidental rates in the 'Manten-Kirari' and common buckwheat groups did not differ when compared to controls. Therefore, these abnormalities may be caused by natural generation. Based on these results, we concluded that dough at a dose of 5,000 mg flour/kg is at a non effect level.
Asunto(s)
Fagopyrum/efectos adversos , Rutina/efectos adversos , Animales , Bronquios/efectos de los fármacos , Dieta , Fagopyrum/química , Femenino , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Masculino , Hipófisis/efectos de los fármacos , Proteínas/metabolismo , RatasRESUMEN
BACKGROUND: Accumulating evidence suggests an association between autism spectrum disorders (ASD) and inflammation in brain regions related to cognitive function. The natural flavonoid luteolin has antioxidant, anti-inflammatory, mast cell-blocking, and neuroprotective effects. It was shown to improve cognitive performance in a mouse model of ASD, but its effect in humans has not been adequately studied. OBJECTIVES: The goal of this study was to assess the effectiveness and tolerability in white children with ASD of a dietary supplement containing 2 flavonoids (>95% pure), luteolin (100 mg/capsule, from chamomile) and quercetin (70 mg/capsule), and the quercetin glycoside rutin (30 mg/capsule) from the Sophora japonica leaf, formulated in olive kernel oil to increase oral absorption. METHODS: Fifty children (4-10 years old; 42 boys and 8 girls) with ASD were enrolled in a 26-week, prospective, open-label trial at the 2nd University Department of Psychiatry at "Attikon" General Hospital, Athens, Greece. Children were referred for the study by their respective physicians or came from the practice of the senior author. ASD diagnosis by clinical assessment was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, symptom list and corroborated by using the Autism Diagnostic Observation Schedule. The dose of the study formulation used was 1 capsule per 10 kg weight per day with food. The primary outcome measures were the age-equivalent scores in the Vineland Adaptive Behavior Scales domains. Secondary outcomes included the Aberrant Behavior Checklist, the Autism Treatment Evaluation Checklist, and the Clinical Global Impression-Improvement score. Data were measured at baseline, week 18, and week 26. Parents were interviewed for any possible improvements they noticed and instructed to report any unusual adverse events. RESULTS: A total of 40 children completed the protocol. There was a significant improvement in adaptive functioning as measured by using the VABS age-equivalent scores (8.43 months in the communication domain, 7.17 months in daily living skills, and 8 months in the social domain; P < 0.005), as well as in overall behavior as indicated by the reduction (26.6%-34.8%) in Aberrant Behavior Checklist subscale scores. Age, sex, and history of allergies had no effect on the results, whereas the initial level of functioning or difficulty did predict the final outcome in most of the measures used. There was a transient (1-8 weeks) increased irritability in 27 of the 50 participants. CONCLUSIONS: These results are encouraging in that the combination of the flavonoids luteolin and quercetin seemed to be effective in reducing ASD symptoms, with no major adverse effects. ClinicalTrials.gov identifier: NCT01847521.
Asunto(s)
Antiinflamatorios/farmacología , Trastornos Generalizados del Desarrollo Infantil/tratamiento farmacológico , Luteolina/farmacología , Quercetina/farmacología , Administración Oral , Antiinflamatorios/administración & dosificación , Antiinflamatorios/efectos adversos , Niño , Trastornos Generalizados del Desarrollo Infantil/fisiopatología , Preescolar , Suplementos Dietéticos , Combinación de Medicamentos , Femenino , Grecia , Humanos , Luteolina/administración & dosificación , Luteolina/efectos adversos , Masculino , Proyectos Piloto , Estudios Prospectivos , Quercetina/administración & dosificación , Quercetina/efectos adversos , Rutina/administración & dosificación , Rutina/efectos adversos , Rutina/farmacología , Resultado del TratamientoRESUMEN
CONTEXT: The number of patients with cancer is increasing. New therapeutic agents to overcome drug-resistant tumors are urgently needed. Cyrtosperma johnstonii N.E. Br. (Araceae) is used for treatment of cancer in Thai traditional medicine. This study aimed to evaluate antioxidant activity and cytotoxicity of C. johnstonii extracts on human cancer cells. MATERIALS AND METHODS: Dried powder of C. johnstonii rhizomes was extracted with several solvents. The 0.1 mg/ml extract solution was tested for antioxidant activity by 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and ferric reducing antioxidant power (FRAP) assays. Color formation from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was used to determine cell viability. Standardization of the extract was performed by high-performance liquid chromatography (HPLC) with photodiode array detector at 254 and 360 nm. Cell cycle arrest was evaluated by flow cytometry after 5 min, 12 h and 24 h treated with 20 µg/ml of the acetone extract. RESULTS: The acetone extract exhibited the highest phenolic content and antioxidant activity (TEAC and EC values = 19.2 ± 0.14 and 19.2 ± 0.31 mM/mg, respectively). The IC50 values for leukemia ranged from 11 ± 1 to 29 ± 3 µg/ml and from 5 ± 2 to 6 ± 0 µg/ml for small cell lung carcinoma cells. Cell cycle arrest occurred at the G2/M phase followed by apoptosis. HPLC analysis revealed that rutin is the major constituents of the extract. DISCUSSION AND CONCLUSION: The acetone extract of C. johnstoni is a promising source of natural antioxidants and anticancer. The extract inhibits cancer cells effectively with less effect on normal cells.
Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Antioxidantes/farmacología , Cyrtosperma/química , Resistencia a Antineoplásicos , Leucemia Eritroblástica Aguda/tratamiento farmacológico , Extractos Vegetales/farmacología , Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológico , Acetona/química , Antineoplásicos Fitogénicos/efectos adversos , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Antioxidantes/efectos adversos , Antioxidantes/química , Antioxidantes/aislamiento & purificación , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Etnofarmacología , Fase G2/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Leucemia Eritroblástica Aguda/metabolismo , Fenoles/efectos adversos , Fenoles/análisis , Fenoles/farmacología , Extractos Vegetales/efectos adversos , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Rizoma/química , Rutina/efectos adversos , Rutina/análisis , Rutina/farmacología , Carcinoma Pulmonar de Células Pequeñas/metabolismo , Solventes/química , TailandiaRESUMEN
CONTEXT: In the Indian traditional system of medicine, Melothria heterophylla (Lour.) Cogn., (Cucurbitaceae) is prescribed for the treatment of diabetes mellitus. OBJECTIVE: In the present study, the antidiabetic effect of ethanol extract of Melothria heterophylla (EEMH), and its active isolated constituents were investigated in streptozotocin (STZ)-induced diabetic Swiss albino rats. METHOD: Successive Soxhlet extraction of the dried total aerial parts with petroleum ether for defatting and then with ethanol (95%) to obtain ethanol extract, which was concentrated under reduced pressure. Hyperglycemia was induced in rats by STZ (50 mg/kg, body weight). Twenty-four hours after STZ induction, respective groups of diabetic rats received EEMH (200 and 400 mg/kg, body weight), gallic acid (GA) (2 and 4 mg/kg, body weight), and rutin (RU) (2 and 4 mg/kg, body weight), respectively, orally daily for 15 days. Glibenclamide (0.5 mg/kg, orally) served as reference. Blood glucose levels and change in body weight were measured on every 5(th) day during 15 days of treatment. Biochemical parameters, viz., serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP) and serum insulin, were measured. RESULTS: EEMH and its active constituents significantly (p < 0.01) normalized blood glucose levels and serum biochemical parameters as compared to those of STZ controls. Both GA (4 mg/kg) and RU (4 mg/kg) exhibited maximum glucose lowering effect (69.1 and 66.7%, respectively) in diabetic rats compared to the other dose (2 mg/kg) at the end of the study. EEMH, gallic acid and RU also showed significant increase in serum insulin, and body weight of STZ-induced diabetic rats. CONCLUSION: Therefore, ethanol extract of Melothria heterophylla, GA and RU demonstrated remarkable antidiabetic activity in STZ-induced diabetic rats.
Asunto(s)
Cucurbitaceae/química , Diabetes Mellitus Experimental/tratamiento farmacológico , Hiperglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Fitoterapia , Componentes Aéreos de las Plantas/química , Extractos Vegetales/uso terapéutico , Animales , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/fisiopatología , Etnofarmacología , Ácido Gálico/administración & dosificación , Ácido Gálico/efectos adversos , Ácido Gálico/aislamiento & purificación , Ácido Gálico/uso terapéutico , Insuficiencia Hepática/complicaciones , Insuficiencia Hepática/prevención & control , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/aislamiento & purificación , India , Insulina/sangre , Insulina/metabolismo , Secreción de Insulina , Hígado/efectos de los fármacos , Hígado/fisiopatología , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificación , Ratas , Rutina/administración & dosificación , Rutina/efectos adversos , Rutina/aislamiento & purificación , Rutina/uso terapéutico , Estreptozocina , Pruebas de Toxicidad Aguda , Pérdida de Peso/efectos de los fármacosRESUMEN
WHAT IS KNOWN AND OBJECTIVE: We report a case of severe liver dysfunction exacerbated after interferon beta (IFNB)-1b injection in a patient with multiple sclerosis (MS) who had been taking a melilot (sweet clover) supplement. Although IFNB-1b therapy for MS can cause mild liver dysfunction, severe hepatotoxicity attributable to supplement use has been reported. CASE SUMMARY: A 23-year-old Japanese woman taking a melilot supplement containing coumarin at 10 mg/day for 3 years was admitted to our hospital to receive IFNB-1b therapy for MS. Fourteen days after subcutaneous injection of IFNB-1b every other day, her aspartate transaminase (AST) and alanine aminotransferase (ALT) levels were elevated at 235 and 681 IU/L, respectively. After the discontinuation of IFNB-1b therapy and supplement intake, AST and ALT returned to normal levels. Later, she started receiving an intramuscular injection of IFNB-1a weekly without supplement intake. She was able to continue IFNB-1a therapy this time, showing a slight elevation of AST level at 61 IU/L. WHAT IS NEW AND CONCLUSION: The combination of IFNB-1b therapy and melilot supplement intake may cause severe liver dysfunction in patients with MS. Given the doubtful value of the supplement, we suggest that it should be avoided by patients receiving interferon therapy.
Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Cumarinas/efectos adversos , Interferón beta/efectos adversos , Resinas de Plantas/efectos adversos , Rutina/efectos adversos , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Adyuvantes Inmunológicos/uso terapéutico , Alanina Transaminasa/metabolismo , Aspartato Aminotransferasas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/fisiopatología , Cumarinas/administración & dosificación , Combinación de Medicamentos , Femenino , Interacciones de Hierba-Droga , Humanos , Inyecciones Intramusculares , Inyecciones Subcutáneas , Interferon beta-1b , Interferón beta/administración & dosificación , Interferón beta/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Resinas de Plantas/administración & dosificación , Rutina/administración & dosificación , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
The use of systemic enzyme therapy in combination with antibiotics in the treatment of urogenital chlamydia infection in patients of both sexes proved to improve the therapeutic efficacy and to reduce the risk of the side effects.
Asunto(s)
Antibacterianos/administración & dosificación , Azitromicina/administración & dosificación , Bromelaínas/administración & dosificación , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/inmunología , Rutina/análogos & derivados , Tripsina/administración & dosificación , Adolescente , Adulto , Antibacterianos/efectos adversos , Azitromicina/efectos adversos , Bromelaínas/efectos adversos , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Rutina/administración & dosificación , Rutina/efectos adversos , Tripsina/efectos adversosRESUMEN
OBJECTIVE: To compare the effectiveness and safety of the triple combination Phlogenzym (rutoside, bromelain, and trypsin) with double combinations, the single substances, and placebo. DESIGN: Multinational, multicentre, double blind, randomised, parallel group design with eight groups structured according to a factorial design. SETTING: Orthopaedic surgery and emergency departments in 27 European hospitals. PARTICIPANTS: A total of 721 patients aged 16-53 years presenting with acute unilateral sprain of the lateral ankle joint. PRIMARY EFFICACY CRITERIA: (a) Pain on walking one or two steps, as defined by the patient on a visual analogue scale. (b) The range of motion, as measured by the investigator and expressed as a sum of flexion and extension. (c) The volume of the injured ankle measured with a volometer. RESULTS: At the primary end point at seven days, the greatest reduction in pain was in the bromelain/trypsin group (73.7%). The Phlogenzym group showed a median reduction of 60.3%, and the placebo group showed a median reduction of 73.3%. The largest increase in range of motion (median) was in the placebo group (60% change from baseline). The Phlogenzym group showed a median increase of 42.9%. The biggest decrease in swelling was in the trypsin group (3.9% change from baseline). The Phlogenzym group showed a -2.30% change from baseline and the placebo group a -2.90% change. In the subgroup analysis of patients who did not use a Caligamed brace, Phlogenzym was superior to placebo for the summarising directional test of the primary efficacy criteria (MW = 0.621; LB-CI 0.496; p = 0.029; one sided Wei-Lachin procedure). The vast majority of doctors and patients rated the tolerability of all treatments tested as very good or at least good. CONCLUSIONS: Phlogenzym was not found to be superior to the three two-drug combinations, the three single substances, or placebo for treatment of patients with acute unilateral sprain of the lateral ankle joint. The small subgroup of patients treated without the support of a Caligamed brace showed evidence of superiority of Phlogenzym over placebo. Further research is warranted to study this effect of Phlogenzym in patients treated without ankle support.
Asunto(s)
Traumatismos del Tobillo/tratamiento farmacológico , Bromelaínas/uso terapéutico , Ligamentos Laterales del Tobillo/lesiones , Rutina/análogos & derivados , Rutina/uso terapéutico , Tripsina/uso terapéutico , Adolescente , Adulto , Bromelaínas/administración & dosificación , Bromelaínas/efectos adversos , Método Doble Ciego , Combinación de Medicamentos , Quimioterapia Combinada , Humanos , Persona de Mediana Edad , Pomadas , Dolor/tratamiento farmacológico , Dimensión del Dolor , Rango del Movimiento Articular , Rutina/administración & dosificación , Rutina/efectos adversos , Esguinces y Distensiones/tratamiento farmacológico , Resultado del Tratamiento , Tripsina/administración & dosificación , Tripsina/efectos adversosRESUMEN
An assessment was carried out of clinical effectiveness of the drug phlogenzym in 74 patients with remitting, remitting-progressive, and secondary progressive course of multiple sclerosis. Phlogenzym intake for up to one to three years resulted in decline in the incidence of complications, with their degree having come to be lower, duration of remissions longer, progression of the illness slowed down. The data secured suggest to us that phlogenzym is a safe agent. It can, we believe used in a therapeutic regimen for those patients presenting with remitting and remitting-progressive types of the course of the disease.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Bromelaínas/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Rutina/análogos & derivados , Rutina/uso terapéutico , Tripsina/uso terapéutico , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Adolescente , Adulto , Encéfalo/efectos de los fármacos , Encéfalo/patología , Bromelaínas/administración & dosificación , Bromelaínas/efectos adversos , Combinación de Medicamentos , Electroencefalografía , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/inmunología , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Crónica Progresiva/inmunología , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/inmunología , Rutina/administración & dosificación , Rutina/efectos adversos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Tripsina/administración & dosificación , Tripsina/efectos adversosAsunto(s)
Bromelaínas/uso terapéutico , Osteoartritis de la Rodilla/tratamiento farmacológico , Rutina/análogos & derivados , Rutina/uso terapéutico , Tripsina/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Bromelaínas/efectos adversos , Combinación de Medicamentos , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Rutina/efectos adversos , Resultado del Tratamiento , Tripsina/efectos adversosRESUMEN
Proteolytic enzymes have analgesic, effects, besides the wellknown antiinflammatory and edema-reducing properties. These analgesic effects are based on the inhibition of inflammation and in addition to that on direct influences on the nociceptors. All that explains the therapeutical effects of such enzymes in degenerative-rheumatic and soft tissue rheumatic diseases in which inflammatory or immunologic processes are not in the forefront. In recent years a significant reduction of pain in various rheumatic diseases, concerning these aspects, was shown in several clinical studies. The clinical trial in patients with periarthritis of shoulder showed statistical equivalence of pain reduction, whether they were treated with phlogenzym or diclofenac. Likewise in the trial of patients suffering from painful osteoarthritis of the knee, there was a statistical equivalence of the pain-scores, comparing diclofenac and enzymes. The study of painful vertebral syndromes again resulted in equivalence of the treatment with NSAIDs compared to therapy with enzymes.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Bromelaínas/uso terapéutico , Osteoartritis/tratamiento farmacológico , Periartritis/tratamiento farmacológico , Rutina/análogos & derivados , Tripsina/uso terapéutico , Adulto , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Bromelaínas/efectos adversos , Ensayos Clínicos como Asunto , Diclofenaco/efectos adversos , Diclofenaco/uso terapéutico , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Rutina/efectos adversos , Rutina/uso terapéutico , Tripsina/efectos adversosRESUMEN
Clinical efficacy of the antiphlogistic potency of enzymes (Wobenzym, 4 x 7 capsules/day) vs. Diclofenac-Na (2 x 50 mg capsules/day) on patients (n = 80) suffering from osteoarthritis of the knee in an acute phase was evaluated. The study design was double blind according to the GCP-guidelines. The treatment period lasted 28 days and was followed by a treatment-free controll-period of another 28 days. There was equal status of age, sex, duration and impact of osteoarthritis in both groups. The clinical parameters as pain at rest, on motion, on walking, at night and pain tenderness showed a significant improvement (p < 0.05) after the treatment period, with tendency to relapse in the following observation period. No significant difference between both treatment-groups could be seen. No changes in laboratory findings were observed. The global-assessment (physician's and patient's score) of efficacy and tolerability in both groups were mostly stated as "very good" and "good". Adverse events were reported as: Wobenzym: total 14 patients: gastrointestinal complaints (obstipation, vomiting, meteorism), allergic rash once and dizziness twice, 6 of these patients discontinued by that reasons. Diclofenac: total 11 patients: gastrointestinal complaints (epigastrical pain, upset stomach, meteorism), dizziness, 3 of these discontinued. All of these vanished after intake was stopped. Summarizing up it could be demonstrated that both evaluated drugs showed equal clinical potency. So it might be assumed that Wobenzym can be used as an alternative substance in treatment of acute painful osteoarthritis.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Diclofenaco/administración & dosificación , Hidrolasas/administración & dosificación , Rodilla , Osteoartritis/tratamiento farmacológico , Rutina/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/efectos adversos , Diclofenaco/efectos adversos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Combinación de Medicamentos , Femenino , Humanos , Hidrolasas/efectos adversos , Masculino , Persona de Mediana Edad , Osteoartritis/diagnóstico , Dimensión del Dolor , Rutina/efectos adversosRESUMEN
The authors of this clinical study report the results of a controlled clinical trial in randomized parallel groups (Wobenzym vs. diuretics) of 55 female patients suffering from brachial arm lymph edema subsequent to ablatio mammae. All patients received manual and machine lymph drainage as well as gymnastics as concomitant therapy. After 7 weeks of therapy the results of the volometric assessments of the arm, the circumference of the arm and the skinfold thickness showed significant improvements compared to diuretics. In addition, the patients receiving Wobenzym reported a significantly higher proportion of patients free of pain compared to the diuretics patients. Overall safety assessment results are satisfactory thus resulting in a superior benefit/risk relation of the Wobenzym group.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Diuréticos/administración & dosificación , Hidrolasas/administración & dosificación , Escisión del Ganglio Linfático , Linfedema/tratamiento farmacológico , Mastectomía , Complicaciones Posoperatorias/tratamiento farmacológico , Rutina/administración & dosificación , Adyuvantes Inmunológicos/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Diuréticos/efectos adversos , Combinación de Medicamentos , Femenino , Humanos , Hidrolasas/efectos adversos , Linfedema/etiología , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Rutina/efectos adversos , Resultado del TratamientoRESUMEN
Warfarin overdose leads to hypoprothrombinemia and bleeding diathesis. We report here the case of a 47 year old woman who ingested an overdose of a non-steroidal anti-inflammatory drug, sold in Mexico under the name of Wobenzym (R), and containing, according to the manufacturer: pancreatin, bromelin, papain, lipase, amylase, trypsin, alpha chymotrypsin and rutin. She developed skin, urinary and gastrointestinal bleeding and was found to be apparently under the effect of a coumadin overdose, i.e. prolonged prothrombin time, prolonged activated thromboplastin time, and low functional and antigenic levels of prothrombin. A platelet count, and the thrombin, reptilase and bleeding times were normal. All laboratory and clinical abnormalities reverted to normal by using fresh frozen plasma and parenteral vitamin K. In addition, we were able to show that the commercial preparation could prolong the prothrombin time in rabbits and, by high-performance liquid chromatography, a pike consonant with purified coumadin was found in the drug. It is concluded that this drug is probably contaminated by coumadin, and that physicians must be aware of its potential side effects.
Asunto(s)
Cumarinas/envenenamiento , Contaminación de Medicamentos , Trastornos Hemorrágicos/inducido químicamente , Hidrolasas/efectos adversos , Hipoprotrombinemias/inducido químicamente , Rutina/efectos adversos , Animales , Pruebas de Coagulación Sanguínea , Cromatografía Liquida , Cumarinas/aislamiento & purificación , Combinación de Medicamentos , Sobredosis de Droga , Femenino , Humanos , Hidrolasas/química , Persona de Mediana Edad , Extractos Vegetales/química , Conejos , Rutina/química , AutoadministraciónRESUMEN
A 54-year-old female patient was treated by a homoeopathic physician with non-orthodox enzyme therapy because of complaints pointing to multiple sclerosis. The therapy consisted of courses of German enzyme preparations (Wobe-Mugos injections, Wobenzym tablets and Wobe-Mugos suppositories), each of which lasted three weeks. During the third course the patient developed a circulatory shock immediately following an injection. She recovered successfully in hospital. On inquiry it became evident that symptoms of tightness, light-headedness and dry mouth had already occurred after a previous injection. In connection with this case a table is presented which reviews the alternative therapies that have been associated with anaphylactic or anaphylactoid reactions.